Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07906080 |
| Title | A Multicenter, Phase I Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (FOCUS) |
| Acronym | FOCUS |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Istituto Oncologico Veneto IRCCS |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | ITA |